Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Persistent Multiple Myeloma.

Trial Profile

Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Persistent Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Lenalidomide; Vorinostat
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
    • 16 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 08 Sep 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top